NLRP3 and diabetes mellitus: In addition, treatment with either MCC-950 (NLRP3 inhibitor) or anakinra (IL-1ra) reverses the cardiac electrical remodelling and decreases the incidence of arrhythmias, emphasizing the pathomechanistic relevance of IL-1β and also a novel pharmacological strategy for the treatment of DM-associated arrhythmias.